Published in final edited form as:

J Hepatol. 2017 May ; 66(5): 1101–1103. doi:10.1016/j.jhep.2016.12.028.

Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C

Jason Grebely^{1,*}, Tracy Swan², Matthew Hickman³, Julie Bruneau⁴, Philip Bruggmann⁵, Olav Dalgard⁶, Alain Litwin⁷, Markus Backmund^{8,9}, Gregory J. Dore¹ International Network for Hepatitis in Substance Users

¹The Kirby Institute, UNSW Sydney, Sydney, Australia ²International Network on Hepatitis in Substance Users, New York, United States ³School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom ⁴CRCHUM, Université de Montréal, Montréal, Canada ⁵Arud Centres of Addiction Medicine, Zurich, Switzerland ⁶Department of infectious Diseases, Akershus University Hospital, Lørenskog, Norway ⁷Division of General internal Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States ⁸Ludwig-Maximilians-University, Munich, Germany ⁹Praxiszentrum im Tal Munich, Munich, Germany

To the Editor:

The 2016 EASL Recommendations on Treatment of Hepatitis C provide important international guidance for the clinical management of HCV infection. The guidance is crucial in the environment of rapidly changing direct-acting antiviral (DAA) therapeutics. However, there are inherent contradictions within the EASL Recommendations for people who inject drugs (PWID). The EASL Recommendations state that “Treatment should be considered without delay in individuals at risk of transmitting HCV (e.g., active injection drug users)”, given the potential for preventing HCV transmission and reductions in HCV prevalence at a population-level. Such prioritization is consistent with guidelines from AASLD/IDSA, World Health Organization, and International Network for Hepatitis in Substance Users. Yet, the EASL Recommendations present prescriptive and rigid guidance, including that PWID should “accept to undergo integrated management of their substance use, including syringe exchange program, substitution therapy and other general harm reduction strategies” prior to receiving DAA therapy, and that “HCV treatment for PWID should be considered on an individualized basis and delivered within a multidisciplinary team setting.” Although appropriate drug dependency management and multidisciplinary

*Corresponding author. Address: Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, Australia. Tel.: +61 2 9385 0957; fax: +61 2 9385 0876. jgrebely@kirby.unsw.edu.au.

Conflict of interest

JG is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Cepheid, Gilead Sciences and Merck. MH has received research grants from Gilead and honoraria from Abbvie, MSD, and Gilead. JB is a consultant and has received grants from Gilead Sciences and Merck. OD is a consultant/advisor Abbvie and Merck and has received research grants from Abbvie, Gilead and Merck. AL is a consultant/advisor from Abbvie, Bristol Myers Squibb, Gilead Sciences, Janssen, and Merck, and has received research grants from Gilead Sciences and Merck. GD is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Cepheid, Gilead, Merck, Janssen and Roche.

care are important aspects of care provision for PWID, the indication that they are essential is reflective of the interferon-containing era, is restrictive, and non-evidence based.

Needle/syringe programs, opioid substitution treatment (OST), and other drug treatments are essential components for improving drug user health, prevent infection (and reinfection), and should be available for all PWID. At an individual level, while engagement in these programs should be encouraged, they should not be requirements for HCV therapy. Some cocaine and/or methamphetamine injectors may not be opioid dependent and not eligible to receive OST, and some people who use opioids may not want or need OST.

In the DAA era, HCV treatment should be considered for all PWID. There are no data to support statements within the recommendations that “Drug and alcohol users or any other patients with ongoing social issues and/or history of psychiatric disease, and those with more frequent drug use during therapy, are at risk of lower adherence and reduced likelihood of achieving SVR.” and that “They need to be monitored more closely during therapy and need more intensive multidisciplinary support”. While DAA therapy should be individualized based on the patient, many PWID may not require regular clinic visits and multidisciplinary support.

The 2016 EASL Recommendations also do not distinguish between people who injected drugs at some point in their lifetime and have ceased injecting (“former PWID”), and people who have injected recently (“recent PWID”, with definitions vary from 1–12 months). Among former PWID, there exists a population of people receiving OST, some of whom may be “recent PWID”. Phase III clinical trials often include “former PWID” and people on OST (with no recent drug use), but almost always exclude recent PWID (including those receiving OST with recent drug use).

Among people receiving OST with no recent illicit drug use, *post hoc* analyses of phase II/III trials of DAA therapy have demonstrated that treatment completion, adherence, and SVR12 are similar to those not receiving OST [1-6]. These trials only provide guidance for HCV management among people receiving stable OST with no recent drug use.

Data on DAA treatment outcomes among people receiving OST with recent illicit drug use are now available from the Co-STAR study [7]. Treatment-naïve individuals with HCV genotype 1/4/6 infection receiving “stable” OST (80% adherence to OST appointments in the last three months) were enrolled (recent drug use did not exclude study participation) and treated with elbasvir/grazoprevir for 12 weeks. Overall, 96% completed therapy, >96.5% were >95% adherent and SVR12 was 91% [7], comparable to trials in non-users. Importantly, drug use at baseline (62% all, 47% non-cannabinoids) and during treatment (60% all, 47% non-cannabinoids) did not impact SVR [7]. These data provide strong support for the efficacy and safety of DAA therapy in people receiving stable OST, including those with recent drug use.

Among people with recent illicit drug use (including those not receiving OST), real-world data on DAA treatment outcomes is emerging, with responses ranging from 95–98% [8,9]. However, it is not clear from these studies as to the proportion of people with recent injecting. Future studies on HCV treatment among recent PWID should clearly define the

study population and injecting drug use characteristics. There are ongoing international studies evaluating DAA HCV regimens among people with recent injecting drug use, including SIMPLIFY (sofosbuvir/velpatasvir for 12 weeks; clinicaltrials.gov:) and HERO (randomized trial of directly observed sofosbuvir/velpatasvir therapy vs. patient navigation; clinicaltrials.gov:). Although further data (clinical trial and “real-world”) are needed to guide clinical management among people with recent injecting drug use, DAA HCV treatment should not be withheld from PWID with recent illicit drug use.

We strongly recommend that all PWID are considered for DAA therapy, for the individual level benefits that therapeutic cure brings, with potential population-level benefits on HCV transmission providing further justification for prioritization.

Acknowledgments

Financial support

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships.

References

- [1]. Puoti M, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, et al. ABT-450/r/ombitasvir plus dasabuvir with or without ribavirin in hcv genotype 1-infected patients receiving stable opioid substitution treatment: pooled analysis of efficacy and safety in phase 2 and phase 3 trials. *Hepatology* 2014;60:1135a–1136a.
- [2]. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014;370:1594–1603. [PubMed: 24720703]
- [3]. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevirelbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. *Ann Intern Med* 2015;163:1–13. [PubMed: 25909356]
- [4]. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. In: *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 2016.
- [5]. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. In: *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 2016.
- [6]. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. *J Hepatol* 2015;63:364–369. [PubMed: 25839406]
- [7]. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir/grazoprevir to treat HCV infection in persons receiving opioid agonist therapy: a randomized controlled trial (C-EDGE CO-STAR). *Ann Intern Med* 2016;165:625–634. [PubMed: 27537841]
- [8]. Litwin AH, Agyemang L, Akiyama M, Feinstein A, Heo M, Wong J, et al. High rates of sustained virological response in people who inject drugs treated with all-oral direct acting antiviral regimens. In: *International Symposium on Hepatitis in Substance Users (INHSU 2016)*; 2016 September 7–9, 2016; Oslo, Norway; 2016.

- [9]. Conway B, Raycraft T, Bhutani Y, Kiani G, Shahi R, Singh A, et al. Efficacy of all-Oral HCV therapy in people who inject drugs (Abstract #1992). *Hepatology* 2016;64:990A. [PubMed: 26705089]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript